PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the oncological outcomes and genitourinary and gastrointestinal adverse events in acute and late-phases of iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
UNASSIGNED: We retrospectively evaluated 334 patients treated for localized prostate cancer with low-dose-rate brachytherapy. Bio-chemical relapse-free survival, cause-specific survival, and overall survival were evaluated using Kaplan-Meier method and log-rank test. Incidence of adverse events was calculated using National Cancer Institute common terminology criteria for adverse events, version 5. Logistic regression was used to identify independent predictors of acute and late-phase genitourinary and gastrointestinal adverse events.
UNASSIGNED: National Comprehensive Cancer Network\'s low-, intermediate-, and high-risk groups included 133 (39.8%), 163 (48.8%), and 38 (11.3%) patients, respectively. The 5-year cause-specific survival rate was 100%. The 5-year bio-chemical relapse-free survival rates for the low-, intermediate-, and high-risk groups were 98.3%, 95.8%, and 100%, respectively. One patient had a ≥ grade 3 acute adverse event. The 5-year cumulative ≥ grade 1, ≥ grade 2, and ≥ grade 3 genitourinary adverse event rates were 27.9%, 14.4%, and 0.5%, respectively. The 5-year cumulative ≥ grade 1, ≥ grade 2, and ≥ grade 3 gastrointestinal adverse event rates were 3.1%, 1.5%, and 0.5%, respectively. A high pre-treatment international prostate symptom score and non-use of α1-blockers were associated with an increased risk of acute genitourinary adverse events.
UNASSIGNED: Low-dose-rate brachytherapy had good oncological outcomes, with acceptable adverse event rates. Pre-treatment urinary function and use of α1-blockers may be useful in predicting and preventing acute genitourinary adverse events.
UNASSIGNED: We retrospectively evaluated 334 patients treated for localized prostate cancer with low-dose-rate brachytherapy. Bio-chemical relapse-free survival, cause-specific survival, and overall survival were evaluated using Kaplan-Meier method and log-rank test. Incidence of adverse events was calculated using National Cancer Institute common terminology criteria for adverse events, version 5. Logistic regression was used to identify independent predictors of acute and late-phase genitourinary and gastrointestinal adverse events.
UNASSIGNED: National Comprehensive Cancer Network\'s low-, intermediate-, and high-risk groups included 133 (39.8%), 163 (48.8%), and 38 (11.3%) patients, respectively. The 5-year cause-specific survival rate was 100%. The 5-year bio-chemical relapse-free survival rates for the low-, intermediate-, and high-risk groups were 98.3%, 95.8%, and 100%, respectively. One patient had a ≥ grade 3 acute adverse event. The 5-year cumulative ≥ grade 1, ≥ grade 2, and ≥ grade 3 genitourinary adverse event rates were 27.9%, 14.4%, and 0.5%, respectively. The 5-year cumulative ≥ grade 1, ≥ grade 2, and ≥ grade 3 gastrointestinal adverse event rates were 3.1%, 1.5%, and 0.5%, respectively. A high pre-treatment international prostate symptom score and non-use of α1-blockers were associated with an increased risk of acute genitourinary adverse events.
UNASSIGNED: Low-dose-rate brachytherapy had good oncological outcomes, with acceptable adverse event rates. Pre-treatment urinary function and use of α1-blockers may be useful in predicting and preventing acute genitourinary adverse events.
摘要：
UNASSIGNED：评估碘-125低剂量率近距离放射治疗局部前列腺癌的急性和晚期的肿瘤学结果以及泌尿生殖和胃肠道不良事件。
UNASSIGNED：我们回顾性评估了334例接受低剂量率近距离放射治疗的局限性前列腺癌患者。生化无复发生存率，特定原因的生存，使用Kaplan-Meier方法和log-rank检验评估总生存期。不良事件的发生率是使用美国国家癌症研究所常见的不良事件术语标准计算的。版本5.Logistic回归用于确定急性和晚期泌尿生殖系统和胃肠道不良事件的独立预测因子。
未经评估：国家综合癌症网络的低，中介-，高危人群包括133人(39.8%)，163（48.8%），和38名(11.3%)患者，分别。5年病因特异性生存率为100％。低生化患者的5年无复发生存率，中介-，高危人群占98.3%,95.8%,100%,分别。一名患者出现≥3级急性不良事件。5年累计≥1级、≥2级和≥3级泌尿生殖系统不良事件发生率为27.9%,14.4%,0.5%，分别。5年累计≥1级、≥2级、≥3级胃肠道不良事件发生率为3.1%,1.5%,0.5%，分别。高治疗前国际前列腺症状评分和不使用α1受体阻滞剂与急性泌尿生殖系统不良事件的风险增加相关。
UNASSIGNED：低剂量率近距离放射治疗具有良好的肿瘤学结果，不良事件发生率可接受。治疗前的泌尿功能和α1受体阻滞剂的使用可能有助于预测和预防急性泌尿生殖系统不良事件。
UNASSIGNED：我们回顾性评估了334例接受低剂量率近距离放射治疗的局限性前列腺癌患者。生化无复发生存率，特定原因的生存，使用Kaplan-Meier方法和log-rank检验评估总生存期。不良事件的发生率是使用美国国家癌症研究所常见的不良事件术语标准计算的。版本5.Logistic回归用于确定急性和晚期泌尿生殖系统和胃肠道不良事件的独立预测因子。
未经评估：国家综合癌症网络的低，中介-，高危人群包括133人(39.8%)，163（48.8%），和38名(11.3%)患者，分别。5年病因特异性生存率为100％。低生化患者的5年无复发生存率，中介-，高危人群占98.3%,95.8%,100%,分别。一名患者出现≥3级急性不良事件。5年累计≥1级、≥2级和≥3级泌尿生殖系统不良事件发生率为27.9%,14.4%,0.5%，分别。5年累计≥1级、≥2级、≥3级胃肠道不良事件发生率为3.1%,1.5%,0.5%，分别。高治疗前国际前列腺症状评分和不使用α1受体阻滞剂与急性泌尿生殖系统不良事件的风险增加相关。
UNASSIGNED：低剂量率近距离放射治疗具有良好的肿瘤学结果，不良事件发生率可接受。治疗前的泌尿功能和α1受体阻滞剂的使用可能有助于预测和预防急性泌尿生殖系统不良事件。
